<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2024-02-08T16:27:44.866Z"
        cq:lastModifiedBy="reference-adjustment-service"
        cq:template="/conf/menarini-berlinchemie/settings/wcm/templates/menarini---details-news"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting"
        jcr:uuid="ababffb8-27ea-478a-a08a-023843b51daa"
        sling:resourceType="menarinimaster/components/page"
        dnnNewsIdentifier="8a1c191b-1720-40aa-88de-c68d8076ed34-889">
        <root
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    jcr:primaryType="nt:unstructured"
                    jcr:title="News &amp; Medien"
                    sling:resourceType="menarinimaster/components/internalheader"
                    altValueFromDAM="{Boolean}false"
                    imageFromPageImage="{Boolean}false"
                    titleFromPage="{Boolean}false"/>
                <section
                    jcr:lastModified="{Date}2023-05-23T15:09:53.441Z"
                    jcr:lastModifiedBy="a.messori@adiacent.com"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/section">
                    <wrapper
                        jcr:lastModified="{Date}2023-05-23T15:11:01.995Z"
                        jcr:lastModifiedBy="a.messori@adiacent.com"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/wrapper">
                        <breadcrumb
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/breadcrumb"/>
                    </wrapper>
                </section>
                <container
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-berlinchemie/de/menarini-group-news"
                        structureStart="{Long}0">
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:styleIds="[1684742346871]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <news_data
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/news_data"
                            newsDate="{Date}2018-09-19T08:11:00.000Z">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="9"/>
                            </cq:responsive>
                        </news_data>
                        <title
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2023-06-07T15:16:13.835Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2"/>
                        <image
                            jcr:lastModified="{Long}1707398398186"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/image"
                            displayPopupTitle="true"
                            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-Menarini-Ricerche-miniatura.jpg"
                            imageFromPageImage="{Boolean}false"
                            isDecorative="true"
                            linkTarget="_self"
                            titleValueFromDAM="false">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="2"
                                    width="4"/>
                                <phone
                                    jcr:primaryType="nt:unstructured"
                                    offset="1"
                                    width="10"/>
                            </cq:responsive>
                        </image>
                        <spacer
                            jcr:lastModified="{Date}2023-06-07T15:17:27.212Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="40"/>
                        <text
                            jcr:lastModified="{Long}1707398398189"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/text"
                            text="&lt;p style=&quot;text-align: center;&quot;>&lt;strong>&lt;span>&lt;img alt=&quot;&quot; src=&quot;/Portals/31/Images/notizie/Menarini-Ricerche.jpg&quot; style=&quot;text-align: center;&quot; />&lt;br />&#xa;&lt;/span>&lt;/strong>&lt;/p>&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;strong>&lt;span>Pomezia, September 19, 2018&lt;/span>&lt;/strong> &amp;ndash; Menarini Ricerche will present tomorrow, September 20&lt;sup>th&lt;/sup>, at the 60&lt;sup>th&lt;/sup> Annual Meeting of the Italian Cancer Society (SIC), &lt;strong>new preclinical data showing that pre-treatment with 5-Azacytidine and Decitabine enhances the Antibody-dependent cellular cytotoxicity (ADCC) of the clinical candidate &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/La-nostra-ricerca/MEN1112&quot;>MEN1112&lt;/a>/OBT357 on several Acute Myeloid Leukemia (AML) cell lines.&lt;/strong>&lt;/p>&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span>MEN1112/OBT357 is a monoclonal antibody targeting CD157, a &lt;span style=&quot;color: black; background: white;&quot;>myeloid marker present on leukemia cells. Menarini has partnered with&lt;/span> Oxford BioTherapeutics to conduct the development of the compound&lt;span style=&quot;color: black; background: white;&quot;>. A comprehensive work of preclinical characterization has been already fulfilled&lt;/span> and MEN1112/OBT357 is currently in phase I clinical trial for the treatment of patients with relapsed/refractory (R/R) Acute Myeloid Leukemia (AML). &lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;strong>&lt;span style=&quot;color: black; background: white;&quot;>The experimental results that will be presented strongly suggest&lt;/span>&lt;span> that pre-treatment with 5-Azacytidine and Decitabine enhances the cell killing activity of &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/La-nostra-ricerca/MEN1112&quot;>MEN1112&lt;/a>/OBT357 on SKNO-1, HL60 and K052 cell lines.&lt;/span>&lt;/strong>&lt;/p>&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span>&amp;ldquo;We observed a statistically significant synergism between different doses of MEN1112/OBT357 and 5-Azacytidine and Decitabine on a number of AML cell lines&amp;rdquo; said Monica Binaschi, PhD, Director of the Preclinical and Translational Oncology Department of Menarini Ricerche, &amp;ldquo;These results seem to confirm the immune-modulatory role of 5-Azacytidine and Decitabine&lt;span style=&quot;color: black; background: white;&quot;>,&lt;/span> which may increase the sensitivity&amp;nbsp; of leukemic cells to MEN1112/OBT357. These new findings suggest that pretreatment with these two agents could promote and enhance tumor cell killing activity by MEN1112/OBT357, and &lt;span style=&quot;color: black; background: white;&quot;>provide a strong rationale for evaluating these combinations in clinical trial.&amp;rdquo;&lt;/span>&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span style=&quot;color: black; background: white;&quot;>The poster &amp;ldquo;The ADCC-mediated activity of the de-fucosylated monoclonal antibody MEN1112/OBT357 is increased by pre-treatment with 5-Azacytidine and Decitabine in acute myeloid leukemia cell lines&amp;rdquo;&lt;/span>&lt;span> &lt;span style=&quot;color: black; background: white;&quot;>will be presented &lt;/span>on September 20&lt;sup>th&lt;/sup>, 2018, 12.00-13.00 and on September 21&lt;sup>st, &lt;/sup>2018, 12.00-13.00.&lt;/span>&lt;/p>"
                            textIsRich="true"/>
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </container>
                </container>
            </container>
        </root>
        <cq:featuredimage
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="{Boolean}false"
            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-Menarini-Ricerche-miniatura.jpg"/>
    </jcr:content>
</jcr:root>
